Search

for
Search:

GlossaryAbrocitinib

medication that inhibits enzymes to treat severe eczema

Abrocitinib is a medication that belongs to a class of drugs known as Janus kinase (JAK) inhibitors. It is primarily used to treat moderate to severe atopic dermatitis (eczema) by reducing inflammation and itching. By inhibiting specific enzymes involved in the inflammatory process, abrocitinib helps manage symptoms and improve the quality of life for patients with this chronic skin condition.

Related Terms

Learn

0 / 0 results

— no results

Research

5 / 31 results

research A Case of Atopic Dermatitis with Alopecia Universalis in a Patient Treated with Abrocitinib

11 citations, February 2022 in “JAAD case reports”

Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.

$Effective Treatment of Refractory Alopecia Areata in Pediatric Patients With Oral Abrocitinib$

research Effective Treatment of Refractory Alopecia Areata in Pediatric Patients With Oral Abrocitinib

3 citations, June 2023 in “Journal of cosmetic dermatology”

A new drug, abrocitinib, helped a child with severe hair loss regrow hair.

Abrocitinib Improved Dupilumab-Resistant Severe Atopic Dermatitis with Comorbid Mild Alopecia Areata in a 12-Year-Old Boy: A Case Report with 1-Year Follow-Up

research Abrocitinib Improved Dupilumab-Resistant Severe Atopic Dermatitis with Comorbid Mild Alopecia Areata in a 12-Year-Old Boy: A Case Report with 1-Year Follow-Up

April 2024 in “Journal of asthma and allergy”

Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.

Forecasting Phase 3 Dose-Response for Abrocitinib, an Oral Janus Kinase 1 Selective Inhibitor, Using Investigator’s Global Assessment and Eczema Area and Severity Index

research Forecasting Phase 3 Dose-Response for Abrocitinib, an Oral Janus Kinase 1 Selective Inhibitor, Using Investigator’s Global Assessment and Eczema Area and Severity Index

September 2019 in “Journal of Investigative Dermatology”

Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.

research The Janus Kinase 1 Inhibitor Abrocitinib for the Treatment of Oral Lichen Planus

7 citations, March 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”

View more "abrocitinib" in research →

Community Join

0 / 0 results

— no results